Melanosis, Neurocutaneous disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

NCMS MCID: MLN073 MIFTS: 45	Melanosis, Neurocutaneous (NCMS) Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Melanosis, Neurocutaneous

MalaCards integrated aliases for Melanosis, Neurocutaneous:

Name: Melanosis, Neurocutaneous ⁵⁷ ¹⁹ ⁷³ ³⁸

Neurocutaneous Melanosis ¹⁹ ⁵⁸ ⁷⁵ ⁷¹

Neurocutaneous Melanocytosis ⁵⁸ ²⁸ ⁵

Neuromelanosis ⁵⁷ ⁷³

Ncms ⁵⁷ ⁷³

Neurocutaneous Melanosis, Somatic ⁵⁷

Neurocutaneous Melanosis Syndrome ¹⁹

Melanosis Coli ⁷¹

Melanosis ⁷¹

Ncm ⁵⁸

Characteristics:

Inheritance:

Somatic mutation ⁵⁷

Prevelance:

Neurocutaneous Melanocytosis: 1-9/100000 (Europe) ⁵⁸

Age Of Onset:

Neurocutaneous Melanocytosis: Childhood ⁵⁸

OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Miscellaneous:
onset in first years of life
some patient may be asymptomatic

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Neuronal diseases Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Benign neoplasms

Melanocytic naevi

Melanocytic naevi of lower limb, including hip

Melanocytic naevi of other and unspecified parts of face

Melanocytic naevi of scalp and neck

Melanocytic naevi of trunk

Melanocytic naevi of upper limb, including shoulder

Orphanet: ⁵⁸

Rare neurological diseases

Rare skin diseases

Sources

Summaries for Melanosis, Neurocutaneous

OMIM®: ⁵⁷ Neurocutaneous melanosis, or neuromelanosis, is characterized by the presence of melanin-producing cells within the brain parenchyma or leptomeninges, which may lead to clinically apparent neurologic signs and symptoms, such as seizures. Other neurologic abnormalities, including hydrocephalus, arachnoid cysts, tumors, and syringomyelia, may also occur. The disorder is a rare but severe manifestation of congenital melanocytic nevus syndrome (CMNS; 137550). Some patients with neurocutaneous melanosis or CMNS may develop malignant melanoma. The incidence of neurologic involvement, development of malignant melanoma, and death is significantly associated with the projected adult size of the largest congenital melanocytic nevus, particularly those greater than 40 cm (summary by Kinsler et al., 2008; Kinsler et al., 2013). (249400) (Updated 08-Dec-2022)

MalaCards based summary: Melanosis, Neurocutaneous, also known as neurocutaneous melanosis, is related to large congenital melanocytic nevus and diffuse leptomeningeal melanocytosis. An important gene associated with Melanosis, Neurocutaneous is NRAS (NRAS Proto-Oncogene, GTPase). The drugs Azelaic acid and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include skin, amygdala and spinal cord, and related phenotypes are intellectual disability and seizure

GARD: ¹⁹ Neurocutaneous melanosis (NCM) is a rare, non-inherited condition of the central nervous system. It is characterized by melanocytic nevi in both the skin and the brain. Two-thirds of people with NCM have giant congenital melanocytic nevi, and the remaining one-third have numerous lesions but no giant lesions. The typical cutaneous lesions are present at birth. Neurological features typically present in the first or second year. Intracranial hypertension is the most common presentation, along with seizures, decreased alertness, and cranial nerve dysfunction.The underlying cause, while not completely understood, is believed to be a primary defect in the neural crest.

Orphanet: ⁵⁸ Neurocutaneous melanocytosis (NCM) is a rare congenital neurological disorder characterized by abnormal aggregations of nevomelanocytes within the central nervous system (leptomeningeal melanocytosis) associated with large or giant congenital melanocytic nevi (CMN; see this term). NCM can be asymptomatic or present as variably severe and progressive neurological impairment, sometimes resulting in death.

UniProtKB/Swiss-Prot: ⁷³ A rare congenital disease characterized by the presence of giant or multiple melanocytic nevi on the skin, foci of melanin-producing cells within the brain parenchyma, and infiltration of leptomeninges by abnormal melanin deposits. Neurologic abnormalities include seizures, hydrocephalus, arachnoid cysts, tumors, and syringomyelia. Some patients may develop malignant melanoma.

Wikipedia: ⁷⁵ Neurocutaneous melanosis is a congenital disorder characterized by the presence of congenital... more...

Sources

Related Diseases for Melanosis, Neurocutaneous

Diseases related to Melanosis, Neurocutaneous via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)

#	Related Disease	Score
1	large congenital melanocytic nevus	11.3
2	diffuse leptomeningeal melanocytosis	11.2
3	scalp syndrome	11.2
4	melanocytic nevus syndrome, congenital	11.1
5	melanoma in congenital melanocytic nevus	10.9
6	hydrocephalus	10.8
7	dandy-walker syndrome	10.7
8	melanoma	10.7
9	intracranial hypertension	10.4
10	rapidly involuting congenital hemangioma	10.4
11	lipomatosis, multiple	10.3
12	meningeal melanoma	10.3
13	melanomatosis	10.3
14	primary melanoma of the central nervous system	10.3
15	arachnoid cysts, intracranial	10.3
16	hydrocephalus, congenital, 1	10.3
17	spinal cord disease	10.3
18	meningeal melanocytoma	10.3
19	meningeal melanomatosis	10.3
20	skin melanoma	10.3
21	tièche-jadassohn nevus	10.3
22	obstructive hydrocephalus	10.2
23	neural tube defects	10.2
24	cerebral cavernous malformations	10.1
25	schimmelpenning-feuerstein-mims syndrome	10.1
26	meningioma, familial	10.1
27	encephalocraniocutaneous lipomatosis	10.1
28	tethered spinal cord syndrome	10.1
29	communicating hydrocephalus	10.1
30	focal epilepsy	10.1
31	lipomatosis	10.1
32	skin benign neoplasm	10.1
33	syringomyelia	10.1
34	amelanotic melanoma	10.1
35	diffuse meningeal melanocytosis	10.1
36	neurofibroma	10.1
37	idiopathic syringomyelia	10.1
38	quadriplegia	10.0
39	spinal cord lipoma	10.0
40	hypertrichosis	10.0
41	ovarian cyst	10.0
42	neuroblastoma	10.0
43	coloboma of macula	10.0
44	ehlers-danlos syndrome, arthrochalasia type, 1	10.0
45	glioma susceptibility 1	10.0
46	hirschsprung disease 1	10.0
47	systemic lupus erythematosus	10.0
48	melanoma, cutaneous malignant 1	10.0
49	nevus, epidermal	10.0
50	capillary malformations, congenital	10.0

Graphical network of the top 20 diseases related to Melanosis, Neurocutaneous:

Sources

Symptoms & Phenotypes for Melanosis, Neurocutaneous

Human phenotypes related to Melanosis, Neurocutaneous:

⁵⁸ ³⁰ (show all 35)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	intellectual disability ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001249
2	seizure ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001250
3	numerous congenital melanocytic nevi ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0005603
4	generalized hirsutism ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002230
5	generalized hyperpigmentation ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0007440
6	thickened skin ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001072
7	eeg abnormality ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002353
8	behavioral abnormality ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000708
9	abnormality of retinal pigmentation ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0007703
10	cranial nerve paralysis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0006824
11	melanoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002861
12	renal hypoplasia/aplasia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0008678
13	venous thrombosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004936
14	meningocele ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002435
15	chorioretinal coloboma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000567
16	dandy-walker malformation ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001305
17	intracranial hemorrhage ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002170
18	abnormality of neuronal migration ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002269
19	hemiparesis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001269
20	syringomyelia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003396
21	hydrocephalus ³⁰	Occasional (7.5%)		HP:0000238
22	global developmental delay ³⁰	Occasional (7.5%)		HP:0001263
23	meningioma ³⁰	Occasional (7.5%)		HP:0002858
24	choroid plexus papilloma ³⁰	Occasional (7.5%)		HP:0200022
25	arachnoid cyst ³⁰	Occasional (7.5%)		HP:0100702
26	chiari malformation ³⁰	Occasional (7.5%)		HP:0002308
27	infectious encephalitis ³⁰	Occasional (7.5%)		HP:0002383
28	encephalitis ⁵⁸		Occasional (29-5%)
29	melanocytic nevus ⁵⁸		Very frequent (99-80%)
30	neoplasm ⁵⁸		Occasional (29-5%)
31	aplasia/hypoplasia of the cerebellum ⁵⁸		Occasional (29-5%)
32	death in infancy ⁵⁸		Occasional (29-5%)
33	ventriculomegaly ⁵⁸		Occasional (29-5%)
34	arnold-chiari malformation ⁵⁸		Occasional (29-5%)
35	mental deterioration ³⁰			HP:0001268

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Skin Nails Hair Skin:
numerous congenital melanocytic nevi
giant pigmented nevi, often in lumbosacral region

Neoplasia:
susceptibility to malignant melanoma

Neurologic Central Nervous System:
seizures (in some patients)
syringomyelia (in some patients)
parenchymal neuromelanosis
dandy-walker malformation (in some patients)
delayed development (in some patients)
more

Clinical features from OMIM®:

249400 (Updated 08-Dec-2022)

Sources

Drugs & Therapeutics for Melanosis, Neurocutaneous

Drugs for Melanosis, Neurocutaneous (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Azelaic acid

Approved

Phase 4

123-99-9

2266

Ethanol

Approved

Phase 4

64-17-5

702

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Salicylic acid

Approved, Investigational, Vet_approved

Phase 4

69-72-7

338

Zinc cation

Approved, Experimental, Investigational

Phase 4

7440-66-6, 23713-49-7

32051

Zinc oxide

Approved

Phase 4

1314-13-2

Iron

Approved

Phase 4

7439-89-6

29936

Oxybenzone

Approved, Investigational

Phase 4

131-57-7

4632

Avobenzone

Approved, Investigational

Phase 4

70356-09-1

Titanium dioxide

Approved

Phase 4

13463-67-7

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Hydroquinone

Approved, Investigational

Phase 4

123-31-9

785

Fluocinolone acetonide

Approved, Investigational, Vet_approved

Phase 4

67-73-2

6215

Isotretinoin

Approved, Investigational, Nutraceutical

Phase 4

302-79-4, 4759-48-2

5538 444795 5282379

Benzophenone

Experimental

Phase 4

119-61-9

3102

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Cytochrome P-450 CYP3A Inhibitors

Phase 4

Keratolytic Agents

Phase 4

Dermatologic Agents

Phase 4

Antirheumatic Agents

Phase 4

Anti-Infective Agents

Phase 4

Antifungal Agents

Phase 4

Cyclooxygenase Inhibitors

Phase 4

Anti-Inflammatory Agents, Non-Steroidal

Phase 4

Analgesics, Non-Narcotic

Phase 4

Anti-Inflammatory Agents

Phase 4

Analgesics

Phase 4

Salicylates

Phase 4

Photosensitizing Agents

Phase 4

Octylmethoxycinnamate

Phase 4

Terephthalylidene dicamphor sulfonic acid

Phase 4

Pharmaceutical Solutions

Phase 4

Hypoglycemic Agents

Phase 4

Silymarin

Phase 4

Antioxidants

Phase 4

Protective Agents

Phase 4

Sunscreening Agents

Phase 4

Tin Fluorides

Phase 4

Radiation-Protective Agents

Phase 4

glucocorticoids

Phase 4

Coal tar

Approved

Phase 3

8007-45-2

Selenium

Approved, Investigational, Vet_approved

Phase 3

7783-07-5, 7782-49-2

533

Selenious acid

Approved, Investigational

Phase 3

14124-67-5, 7783-00-8

1091

Triamcinolone

Approved, Vet_approved

Phase 2, Phase 3

124-94-7

31307

Anticoagulants

Phase 3

Calcium, Dietary

Phase 3

Trace Elements

Phase 3

Sodium Selenite

Phase 3

Micronutrients

Phase 3

Interventional clinical trials:

(show top 50) (show all 86)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficacy & Safety of Azelaic Acid 15% Gel vs. Hydroquinone 4% Cream in the Treatment of Melasma	Unknown status	NCT00927771	Phase 4	azelaic acid gel;hydroquinone cream
2	Comparing Tranexamic Acid Microinjection Alone Versus Its Combination With Fractional Carbon Dioxide Laser in Melasma Treatment	Unknown status	NCT03899233	Phase 4	Tranexamic acid intradermal microinjections
3	The Efficacy of Oral Tranexamic Acid and a 1927 nm Diode Laser in Patients With Melasma. A Prospective Randomized Split Face Study	Unknown status	NCT03686787	Phase 4	Tranexamic Acid
4	Different Dermatological Approaches in Treatment of Melasma: A Split Face Randomized Clinical Trial	Unknown status	NCT03923062	Phase 4
5	The Efficacy of Combined Peels in Treatment of Melasma Using Modified Jessner's Solution With 20%Trichloroacetic Acid Versus 70%Glycolic Acid With 20% Trichloroacetic Acid : A Split-face Study	Unknown status	NCT03153852	Phase 4	Modified Jessner's solution;Glycolic acid;Trichloroacetic acid
6	Double Blind Randomized Study of 2% Miconazol Versus 4% Hydroquinone in the Treatment for Melasma.	Unknown status	NCT01661556	Phase 4	Miconazole;Hydroquinone
7	A Clinical Usage Study to Evaluate the Safety and Efficacy of an Herbal-Based De-Pigmenting System	Completed	NCT02138539	Phase 4	Hydroquinone
8	A Double Blind Randomized Study Comparing the Ultraviolet (UV) Photoprotection With UV Plus Visible Light Photoprotection in the Treatment of Melasma.	Completed	NCT01695356	Phase 4	290-400 nm sunscreen;290-800 nm sunscreen
9	Open Label Study to Evaluate the Efficacy and Safety of Sequential Therapy With Fluocinolone Acetonide 0.01%, Hydroquinone (HQ) 4% and Tretinoin 0.05% (TriLuma® Cream) and a Series of Glycolic Acid Peels for the Treatment of Melasma	Completed	NCT00472966	Phase 4	Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
10	An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma	Completed	NCT00469183	Phase 4	Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
11	Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma	Completed	NCT00500162	Phase 4
12	Treatment of Melasma With Jessner's Solution vs. Trichloroacetic Acid: A Comparison of Clinical Efficacy	Completed	NCT00166192	Phase 4
13	The Efficacy of Salicylic Acid Peels Combined With 4% Hydroquinone Cream Versus 4% Hydroquinone Cream Alone in the Treatment of Hispanic Women With Moderate to Severe Melasma	Completed	NCT00616239	Phase 4	20-30% Salicylic Acid peels to the right side of the face;20-30% Salicylic Acid peels to the left side of the face
14	THE METFORMIN AND TRICHLOROACETIC ACID IN TREATMENT OF MELASMA	Recruiting	NCT03475524	Phase 4	MetFORMIN 1000 Mg Oral Tablet;Placebos;Trichloroacetic Acid Peeling;MetFORMIN 500 Mg Oral Tablet
15	Trichloroacetic Acid (TCA) Combined With Microdermabrasion in Treatment of Melasma	Not yet recruiting	NCT04823520	Phase 4	TCA
16	Topical Silymarin Versus Combined Topical Silymarin and Microneedling in Treatment of Melasma: Split Face Study	Not yet recruiting	NCT05099601	Phase 4
17	Treatment of Melasma With Stabilized Kligman Preparation Associated or Not With Pulsed Dye Laser; a Comparative Prospective Study	Terminated	NCT00863278	Phase 4	Kligman's Trio
18	Split-Face, Randomized, Open-Label Study of Sequential Treatment With Tri-Luma® Cream With Intense Pulsed Light (IPL) vs. a Mild Inactive Control Cream With Intense Pulsed Light (IPL) in Subjects With Melasma	Terminated	NCT00669071	Phase 4	Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%;Cetaphil® Moisturizing Cream as Inactive Control
19	Oral and 5% Topical Tranexamic Acid in Monotherapy Compared With 4% Topical Hydroquinone for the Treatment of Melasma: Three-arm Randomized, Double-blinded Clinical Trial	Unknown status	NCT03585179	Phase 3	Oral Tranexamic Acid;5% topical tranexamic acid;4% hydroquinone
20	Evaluation of Fractional CO2 Laser and Tranexamic Acid in Treatment of Melasma:Clinical,Histopathological and Immunohistochemical Study	Unknown status	NCT04599205	Phase 2, Phase 3	Tranexamic acid
21	Azelaic Acid Iontophoresis Versus Topical Azelaic Acid Cream in the Treatment of Melasma - An Open Randomized, Controlled, Prospective, Single Blinded Clinical Trial	Unknown status	NCT00848458	Phase 2, Phase 3
22	Evaluation of the Therapeutic Effect of Platelet Rich Plasma in Melasma	Unknown status	NCT03308370	Phase 3
23	Selenite in the Detoxification of Arsenic and the Prevention of Arsenical Melanosis and Cancers Amongst Bangladeshi Arsenicosis Patients: A 48-week, Randomized, Double-blinded, Placebo-controlled Phase III Trial	Completed	NCT01442727	Phase 3	sodium selenite;placebo
24	Comparison of Efficacy of Tranexamic Acid Mesotherapy Versus 0.9% Normal Saline for Melasma; a Split Face Study in Tertiary Care Hospital of Karachi	Completed	NCT04170088	Phase 2, Phase 3	Tranexamic Acid;0.9% Normal Saline
25	Randomized, Controlled, Double-blind Study of Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma	Completed	NCT03751163	Phase 3	Tranexamic Acid Oral Product;Hydroquinone 4% Cream
26	Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study	Completed	NCT02095990	Phase 3	Hydroquinone;Placebo
27	Efficacy of Melanil in the Treatment of Melasma	Completed	NCT01001624	Phase 3
28	Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In The Treatment Of Facial Melasma, Taking As Reference The Product Triluma ® (Hidroquinone, Fluoncinolone And Tretinoin).	Suspended	NCT00717652	Phase 2, Phase 3	arbutin, tretinoin, triamcinolone;Triluma
29	Efficacy of Platelet-rich Plasma in Treatment of Melasma	Completed	NCT03674203	Phase 2
30	An Open-Label Pilot Study Evaluating the Effectiveness and Tolerability of a Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma	Completed	NCT02730819	Phase 2	Illuminate Cream
31	A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma	Completed	NCT03049059	Phase 2	4% hydroquinone cream
32	Comparison of Topical Silymarin With Hydroquinone in the Treatment of Melasma	Completed	NCT03982849	Phase 2	Hydroquinone 4% Cream;silymarin 0.7% cream
33	Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma: a Double Blind Prospective Randomzed Study	Recruiting	NCT05119413	Phase 2	New trio de Kligman;Trio Kligman
34	Comparative Study for the Treatment of Freckles by Intradermal Tranexamic Acid Versus Q Switched KTP Laser (532nm)	Unknown status	NCT03885895	Phase 1	Tranexamic Acid Injectable Product
35	Comparative Study of mMASI Before and After Hyperthyroid Therapy in Hyperthyroid Subjects With Melasma	Completed	NCT04346901	Phase 1	Thiamazol
36	Comparative Study Between Chemical Peeling With 70% Glycolic Acid and Intradermal Transamine for the Treatment of Melasma.	Completed	NCT05362500	Phase 1	Glycolic Acid 70%;Tranexamic acid injection
37	Green Banana Peel Extract for Melasma Treatment	Completed	NCT05031689	Phase 1
38	Spironolactone for the Treatment of Melasma: a Prospective, Open-label Proof-of-concept and Dose-ranging Study	Withdrawn	NCT03953209	Phase 1	Spironolactone 50Mg Tablet;Spironolactone 100Mg Tablet;Spironolactone 200Mg
39	Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma	Withdrawn	NCT02892071	Phase 1	22% TCA peel
40	The Efficacy of Melanostop Peel in Combination With Specifically Selected Home Care Regimen for Improvement of Melasma	Unknown status	NCT03826277
41	A Prospective, Double-blind, Split-body, Randomized Controlled Trial to Assess the Efficacy of Low Level Laser Therapy for Pigmentary Disorders	Unknown status	NCT04308421
42	Efficacy and Safety of Using Combination of 755-nm Picosecond Alexandrite Laser and 2% Hydroquinone Compared With 2% Hydroquinone Alone for the Treatment of Melasma: a Randomized Split-face Controlled Trial	Unknown status	NCT04597203		topical 2% hydroquinone
43	A Split-face Comparison of Low Fluence 1064-nm Q-switched Nd:YAG Laser Plus Vitamin C vs Low Fluence 1064-nm Q-switched Nd:YAG Laser Plus Intradermal Tranexamic Acid Injection for Melasma:a Single Blinded, Randomised Study	Unknown status	NCT03008655
44	Evaluation of the Lutronic PicoPlus for the Treatment of Dematological Conditions Such as Unwanted Tattoos and Benign Pigmented Lesions	Unknown status	NCT03415685
45	Combined Trichlotoaceticacid and Microneedle Versus Trichlroacetic Acid Alone in the Treatment of Melasma	Unknown status	NCT03472235
46	Evaluation of the Lutronic LaseMD System for the Treatment of Melasma	Unknown status	NCT03456674
47	A Pilot Study Comparing the Efficacy of 1064 Q-switch Laser vs. Glycolic Acid Peels for the Treatment of Melasma: A Randomized Control Trial	Completed	NCT01976273
48	Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma	Completed	NCT01850186		Stabilized kilnman trio
49	Study of the Influence of Blue Light Emitted by Computer / Television Screens on Melasma Single-center, Interventional, Randomized, Single-blind Study (Masked Investigator) MELABLUE Study	Completed	NCT03877445
50	Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity. A Prospective Randomized Placebo-controlled Study	Completed	NCT03878433		Glisodin

Search NIH Clinical Center for Melanosis, Neurocutaneous

Sources

Genetic Tests for Melanosis, Neurocutaneous

Genetic tests related to Melanosis, Neurocutaneous:

#	Genetic test	Affiliating Genes
1	Neurocutaneous Melanocytosis ²⁸	NRAS

Sources

Anatomical Context for Melanosis, Neurocutaneous

Organs/tissues related to Melanosis, Neurocutaneous:

MalaCards : Skin, Amygdala, Spinal Cord, Pons, Cerebellum, Brain, Thyroid

Sources

Publications for Melanosis, Neurocutaneous

Articles related to Melanosis, Neurocutaneous:

(show top 50) (show all 706)

#	Title	Authors	PMID	Year
1	Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. ⁶² ⁵⁷ ⁵	Kinsler VA...Moore GE	23392294	2013
2	Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. ⁶² ⁵⁷	Ramaswamy V...Khakoo Y	22469364	2012
3	Complications of congenital melanocytic naevi in children: analysis of 16 years' experience and clinical practice. ⁶² ⁵⁷	Kinsler VA...Atherton DJ	18671780	2008
4	Giant congenital melanocytic nevi: the significance of neurocutaneous melanosis in neurologically asymptomatic children. ⁶² ⁵⁷	Foster RD...Frieden IJ	11252085	2001
5	MR of parenchymal neurocutaneous melanosis. ⁶² ⁵⁷	Demirci A...Duncan C	7793388	1995
6	Neurocutaneous melanosis with malignant leptomeningeal melanoma. A case with metastases outside the nervous system. ⁶² ⁵⁷	Kaplan AM...Lu AT	1180728	1975
7	Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. ⁵	Lim YH...Choate KA	24006476	2014
8	Keratinocytic epidermal nevi are associated with mosaic RAS mutations. ⁵	Hafner C...Real FX	22499344	2012
9	Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis. ⁵	Dessars B...Heimann P	18633438	2009
10	RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. ⁵	Nikiforova MN...Nikiforov YE	12727991	2003
11	GIANT PIGMENTED NEVI, MELANOMA, AND LEPTOMENINGEAL MELANOCYTOSIS: A CLINICAL AND HISTOPATHOLOGICAL STUDY. ⁵⁷	REED WB...NICKEL WR	14237589	1965
12	PRIMARY MENINGEAL MELANOSIS. A CLINICO-PATHOLOGICAL REPORT OF TWO CASES. ⁵⁷	TVETEN L	14276523	1965
13	NEURO-CUTANEOUS MELANOSIS. ⁵⁷	FOX H...YATES PO	14223666	1964
14	Congenital Melanocytic Nevi Syndrome With Leptomeningeal Melanoma. ⁶²	Mohite A...Rangarajan V	35867990	2022
15	Light dependence in the phototrophy-phagotrophy balance of constitutive and non-constitutive mixotrophic protists. ⁶²	Schenone L...Modenutti B	35962828	2022
16	Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRAS-mutant neurocutaneous melanosis. ⁶²	Schweizer L...von Zezschwitz B	35728810	2022
17	Changes in health care utilization and financial protection after integration of the rural and urban social health insurance schemes in Beijing, China. ⁶²	Shi Z...Meng Q	36192795	2022
18	The Forgotten Phacomatoses: A Neuroimaging Review of Rare Neurocutaneous Disorders. ⁶²	Samara A...Eldaya RW	34607749	2022
19	Calycosin protects against oxidative stress-induced cardiomyocyte apoptosis by activating aldehyde dehydrogenase 2. ⁶²	Ding WJ...Liu B	36059198	2022
20	UV-excited blue- to green-emitting Tb3+ -activated sodium calcium metasilicate colour tunable phosphor for luminescence devices. ⁶²	Deepali...Jayasimhadri M	35797222	2022
21	Altered gene expression due to aberrant DNA methylation correlates with responsiveness to anti-EGFR antibody treatment. ⁶²	Otsuki Y...Ishioka C	35403373	2022
22	CSF2-dependent monocyte education in the pathogenesis of ANCA-induced glomerulonephritis. ⁶²	Rousselle A...Schreiber A	35418479	2022
23	Enhanced rate capability and high-voltage cycling stability of single-crystal nickel-rich cathode by surface anchoring dielectric BaTiO3. ⁶²	Jin F...Yuan S	35367925	2022
24	Neuropsychiatric systemic lupus erythematosus in a girl with neurocutaneous melanosis caused by a somatic mutation in NRAS. ⁶²	Inoguchi T...Takahashi T	35238342	2022
25	pH/redox-responsive core cross-linked based prodrug micelle for enhancing micellar stability and controlling delivery of chemo drugs: An effective combination drug delivery platform for cancer therapy. ⁶²	Gebrie HT...Wu SY	35882161	2022
26	A David and Goliath set-up: a qualitative study of the challenges of ensuring the introduction of cost-effective new cancer medicines in Finland. ⁶²	Ollila E...Sailas L	36038900	2022
27	Preclinical safety of negatively charged microspheres (NCMs): Optimization of radiolabeling for in vivo and ex vivo biodistribution studies after topical administration on full-thickness wounds in a rat model. ⁶²	Collantes M...Penuelas I	35697288	2022
28	Managing the medical resources of a national insurance program: lessons based on China's NCMS. ⁶²	Qian W...Cheng X	35820951	2022
29	What fragile factors hinder the pace of China's alleviation efforts of the poverty-stricken population? A study from the perspective of impoverishment caused by medical expenses. ⁶²	Wang J...Li Y	35906603	2022
30	Regulation of Magnetocaloric Effect in Ni40Co10Mn40Sn10 Alloys by Using a Homemade Uniaxial Strain Pressure Cell. ⁶²	Qiao K...Zhang H	35744390	2022
31	Socio-economic inequalities in health service utilization among Chinese rural migrant workers with New Cooperative Medical Scheme: a multilevel regression approach. ⁶²	Li D...Wang X	35659640	2022
32	Effects of Co/Mn Content Variation on Structural and Electrochemical Properties of Single-Crystal Ni-Rich Layered Oxide Materials for Lithium Ion Batteries. ⁶²	You L...Yu A	35588249	2022
33	Neurocutaneous melanosis with an intracranial cystic-solid meningeal melanoma in an adult: A case report and review of literature. ⁶²	Liu BC...Zhang XF	35801056	2022
34	Neurosurgical management of patients with neurocutaneous melanosis: a systematic review. ⁶²	Rahman RK...Mazzola CA	35535823	2022
35	Multifunctional Lanthanide-Doped Binary Fluorides and Graphene Oxide Nanocomposites Via a Task-Specific Ionic Liquid. ⁶²	Sharma RK...Ghosh P	35647428	2022
36	Clinical and Histological Outcomes of Negatively Charged Polystyrene Microspheres Applied Daily Versus Three Times per Week in Hard-to-Heal Diabetic Foot Ulcers: A Randomized Blinded Controlled Trial. ⁶²	Lazaro-Martinez JL...Garcia-Alvarez Y	35635201	2022
37	Public health insurance and enrollees' diet structure in rural China. ⁶²	Chen Q...Tian G	35620627	2022
38	Mitochondrial-Targeted Therapies Require Mitophagy to Prevent Oxidative Stress Induced by SOD2 Inactivation in Hypertrophied Cardiomyocytes. ⁶²	Peugnet V...Dubois-Deruy E	35453408	2022
39	Inhibition of BKCa channels protects neonatal hearts against myocardial ischemia and reperfusion injury. ⁶²	Sanghvi S...Singh H	35393410	2022
40	Melanocytic lesions of the central nervous system: a case series. ⁶²	Varela-Poblete J...Medina-Escobar J	35352754	2022
41	Nitrogen-doped biochar as peroxymonosulfate activator to degrade 2,4-dichlorophenol: Preparation, properties and structure-activity relationship. ⁶²	Jingjing Y...Zhi D	34863564	2022
42	The State-of-the-Art Functionalized Nanomaterials for Carbon Dioxide Separation Membrane. ⁶²	Wong KC...Ma J	35207107	2022
43	Contextual influences on implementation of online behavioral obesity treatment in primary care: formative evaluation guided by the consolidated framework for implementation research. ⁶²	Espel-Huynh HM...Thomas JG	34971381	2022
44	A Synergistic Effect of Na+ and Al3+ Dual Doping on Electrochemical Performance and Structural Stability of LiNi0.88Co0.08Mn0.04O2 Cathodes for Li-Ion Batteries. ⁶²	Park HG...Park K	35041400	2022
45	Single-Cell Analysis Reveals the Role of the Neuropeptide Receptor FPR2 in Monocytes in Kawasaki Disease: A Bioinformatic Study. ⁶²	Wang T...Ji W	35692878	2022
46	Clinicopathological and surgical comparisons of differentiated thyroid cancer between China and the USA: A multicentered hospital-based study. ⁶²	Zhu J...Wei W	36249201	2022
47	Protein phosphatase 2A regulates xanthine oxidase-derived ROS production in macrophages and influx of inflammatory monocytes in a murine gout model. ⁶²	Elsayed S...Elsaid KA	36467056	2022
48	Non-cardiomyocytes in the heart in embryo development, health, and disease, a single-cell perspective. ⁶²	Ding S...Na J	36393852	2022
49	"I didn't feel like a number": The impact of nurse care managers on the provision of buprenorphine treatment in primary care settings. ⁶²	Beharie N...Harocopos A	34688496	2022
50	[An adult case of neurocutaneous melanosis with acute exacerbation after a long asymptomatic period following excision of a melanocytic nevus]. ⁶²	Furukawa K...Ozaki A	34789628	2021

Sources

Genes for Melanosis, Neurocutaneous

Genes related to Melanosis, Neurocutaneous (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	1307.86	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative variation ⁷³ Genetic Tests ²⁸ GeneCards inferred via : Disorders (show sections)	12727991 18633438 22499344 (more) 23392294 24006476

Sources

Variations for Melanosis, Neurocutaneous

ClinVar genetic disease variations for Melanosis, Neurocutaneous:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	NRAS	NM_002524.5(NRAS):c.181C>A (p.Gln61Lys)	SNV	Pathogenic	73058	rs121913254	GRCh37: 1:115256530-115256530 GRCh38: 1:114713909-114713909
2	NRAS	NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)	SNV	Pathogenic	13900	rs11554290	GRCh37: 1:115256529-115256529 GRCh38: 1:114713908-114713908